Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model

Ewing's sarcoma is a rare and aggressive malignancy. In the present study, tumor from a patient with a Ewing's sarcoma with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion was implanted in the right chest wall of nude mice to establish a patient-derived orthotopic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncotarget 2016-07, Vol.7 (30), p.47556-47564
Hauptverfasser:	Murakami, Takashi, Singh, Arun S, Kiyuna, Tasuku, Dry, Sarah M, Li, Yunfeng, James, Aaron W, Igarashi, Kentaro, Kawaguchi, Kei, DeLong, Jonathan C, Zhang, Yong, Hiroshima, Yukihiko, Russell, Tara, Eckardt, Mark A, Yanagawa, Jane, Federman, Noah, Matsuyama, Ryusei, Chishima, Takashi, Tanaka, Kuniya, Bouvet, Michael, Endo, Itaru, Eilber, Fritz C, Hoffman, Robert M
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Bone Neoplasms - drug therapy Bone Neoplasms - pathology Cyclin-Dependent Kinase 4 - antagonists & inhibitors Cyclin-Dependent Kinase 6 - antagonists & inhibitors Cyclin-Dependent Kinase Inhibitor p18 - genetics Doxorubicin - therapeutic use Drug Resistance, Neoplasm Female Humans Imidazoles - therapeutic use Mice Molecular Targeted Therapy Oncogene Proteins, Fusion - genetics Piperazines - therapeutic use Pyrazines - therapeutic use Pyridines - therapeutic use Receptor, IGF Type 1 - antagonists & inhibitors Research Paper RNA-Binding Protein FUS - genetics Sarcoma, Ewing - drug therapy Sarcoma, Ewing - pathology Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!